Retatrutide

Triple-agonist (GLP-1 / GIP / glucagon) studied for dramatic metabolic and weight change.

Studied in the context of

• Promoting significant weight loss (clinical trials showed over 20% body weight reduction in some patients)
• Dramatically improving insulin sensitivity and blood sugar control
• Increasing energy expenditure by enhancing lipolysis (fat breakdown) and fat oxidation
• Suppressing appetite and cravings, leading to reduced caloric intake
• Slowing gastric emptying, which prolongs fullness and further curbs appetite
• Enhancing glucose-dependent insulin secretion (more insulin release when blood sugar is high)
• Reducing glucagon levels and hepatic glucose output, helping to lower fasting blood glucose
• Improving cardiometabolic health markers (like lowering liver fat and possibly improving cholesterol profiles)

GLP-1/GIP/Glucagon · 10mg · For laboratory and research use only. Not for human or animal consumption. 18+ qualified researchers only.